IDEXX Laboratories, Inc. (ETR:IX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 38.03B +41.8% |
| Revenue (ttm) | 3.67B +10.4% |
| Net Income | 902.35M +19.3% |
| EPS | 11.14 +22.6% |
| Shares Out | n/a |
| PE Ratio | 42.15 |
| Forward PE | 38.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 500.80 |
| Previous Close | 489.60 |
| Day's Range | 500.80 - 500.80 |
| 52-Week Range | 478.80 - 663.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 5, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
IDEXX Laboratories to Release 2026 Second Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 second quarter financial results for Tue...
IDEXX Laboratories Transcript: Stifel Jaws & Paws Conference 2026
The new CEO is driving a purpose-led strategy focused on innovation, global expansion, and integrated diagnostics and software. AI and new platforms like inVue Dx and Cancer Dx are fueling growth, with strong adoption and expanding capabilities. The company expects continued momentum from a robust pipeline and sector tailwinds.
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.
IDEXX Laboratories to Present at Stifel Conference and Announces 2026 Investor Day
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, wil...
IDEXX Laboratories Transcript: AGM 2026
The meeting featured a CEO transition, approval of all management proposals including board declassification and special meeting rights for 25% shareholders, and rejection of a shareholder proposal for a 10% threshold. No questions were raised during the Q&A.
IDEXX Laboratories Earnings Call Transcript: Q1 2026
Q1 2026 saw 14% reported and 11% organic revenue growth, with strong gains in CAG Diagnostics, premium instrument placements, and international markets. Full-year guidance was raised for revenue, EPS, and operating margin, supported by innovation and robust customer retention.
IDEXX Laboratories Earnings release: Q1 2026
IDEXX Laboratories released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q1 2026
IDEXX Laboratories has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
IDEXX Laboratories Quarterly report: Q1 2026
IDEXX Laboratories has published its Q1 2026 quarterly earnings report on May 5, 2026.
IDEXX Laboratories Announces First Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company repor...
University of New England launches new Institute of Public and Planetary Health in honor of philanthropist and IDEXX Founder David Evans Shaw
A $5 million gift from the storied entrepreneur, activist, and impact investor will advance the University of New England's work at the intersection of environmental and human health while boosting Ma...
IDEXX Laboratories to Release 2026 First Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tues...
IDEXX Announces UK Availability of Cancer Dx Panel for Early Detection of Canine Lymphoma
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Proxy statement: Proxy filing
IDEXX Laboratories filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Proxy statement: Proxy Filing
IDEXX Laboratories filed a proxy statement on March 13, 2026, providing details for shareholder voting and corporate governance matters.
IDEXX Laboratories Transcript: 47th Annual Raymond James Institutional Investor Conference
A robust innovation-driven strategy is fueling double-digit growth in veterinary diagnostics, supported by expanding international markets, increased pet longevity, and accelerated investment in new platforms and oncology solutions. Long-term targets include 10%+ revenue growth and 15%+ EPS growth.
IDEXX Laboratories Slides: 47th Annual Raymond James Institutional Investor Conference
IDEXX Laboratories has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
IDEXX Laboratories Transcript: BofA Securities Animal Health Summit
Double-digit organic revenue growth and record instrument placements were achieved in 2025, driven by innovation in diagnostic platforms like inVue Dx and Cancer Dx. Despite sector headwinds, recurring revenue and margin expansion are expected to continue in 2026, supported by a stable leadership team.
IDEXX Laboratories to Present at Two Institutional Investor Conferences
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 26, 9:55 am –...
IDEXX Laboratories Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw double-digit organic revenue growth, record instrument placements, and strong EPS gains, driven by innovation and international expansion. 2026 guidance anticipates continued robust growth, margin improvement, and capital returns, despite sector headwinds.
IDEXX Laboratories Annual report: Q4 2025
IDEXX Laboratories has published its Q4 2025 annual report on February 2, 2026.
IDEXX Laboratories Earnings release: Q4 2025
IDEXX Laboratories released its Q4 2025 earnings on February 2, 2026, summarizing the period's financial results.
IDEXX Laboratories Slides: Q4 2025
IDEXX Laboratories has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 2, 2026.